Fast-tracked olaratumab fails to improve sarcoma survival

The US FDA and the European Medicines Agency (EMA) are recommending that no new patients with advanced soft tissue sarcoma start treatment with olaratumab (Lartruvo) due to lack of efficacy. The decisions are based on results from the ANNOUNCE study that showed olaratumab in combination with doxorubicin offers no survival benefit over doxorubicin alone. Clinicians may ...

Already a member?

Login to keep reading.

© 2022 the limbic